Fig. 3

Percentage of patients shifting from HFEM to VLFEM status anytime during the double-blind treatment period and maintaining their shift from HFEM status to VLFEM status for ≥ 3 consecutive months until the end of the study (patients with HFEM at baseline). ***P < .001 versus placebo from logistic regression analysis. Abbreviations: CI, confidence interval; GMB, galcanezumab; HFEM, high-frequency episodic migraine; n, number of patients who were categorized as HFEM at baseline with a baseline value and at least one post-baseline value recorded; OR, odds ratio; VLFEM, very low-frequency episodic migraine